DUBLIN--(BUSINESS WIRE)--The "Cephalosporin Market: Global Opportunity Analysis and Industry Forecast, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
According to this report, the global cephalosporin market size was valued at $11,869 million in 2017, and is estimated to reach $14,022 million by 2025, growing at a CAGR of 2% from 2018 to 2025. The third-generation cephalosporin segment held more than 30% of the total cephalosporin market share in 2017.
The major factors contributing to the growth of the market include increase in incidence of population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea. In addition, increase in R&D activities to develop highly efficient & safe drugs and upsurge in use of combination therapies further boost the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains restrain the market growth.
Based on application, the market is segmented into respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. The respiratory tract infection segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as cephalosporin are used for treatment of both upper & lower respiratory tract infection and lower respiratory infections are the leading infectious causes of death globally.
Hence, oral cephalosporin is used in the treatment of lower and upper respiratory tract infections widely. However, the sexually transmitted infection is expected to register highest CAGR during the forecast period, due to the rising rate of sexually transmitted infections globally and some second-generation cephalosporin and most of the third-generation cephalosporin are effective in the treatment.
Based on generation, the market is classified into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. The third-generation cephalosporin segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as these have a broader spectrum of activity and these are used for the treatment of Gram-negative bacillary meningitis, serious infections of enterobacteriaceae, otitis media, and others. However, the fifth-generation cephalosporin is expected to register highest CAGR of 3.3% during the forecast period.
Based on region, the antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2017, accounting for the highest share, and is anticipated to maintain cephalosporin market trends throughout the forecast period. This is attributed to increased consumption of cephalosporin, its easy availability, and rise in sale of over-the-counter drugs, and increase in bacterial infection in the region. LAMEA is projected to register the highest CAGR of 4.2% during the forecast period, owing to increase in incidence of infectious diseases. In addition, rise in healthcare expenditure is anticipated to offer a lucrative opportunity for the market growth.
The report provides a comprehensive analysis of the key players operating in the global cephalosporin industry, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited (Lupin Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Eli Lilly and Company, Bayer HealthCare, Sun Pharmaceutical, Shionogi, and others.
- Branded cephalosporin segment is expected to register the highest CAGR of 2.3% during the analysis period.
- Based on route of drug administration, the injectable cephalosporin segment accounted for the largest share in 2017 and is expected to maintain its dominance during the forecast period.
- India and China collectively contributed for more than 40% share of the Asia-Pacific cephalosporin market in 2017.
- U.S. was the major shareholder that accounted for more than 90% of the North America cephalosporin market in 2017.
Key Topics Covered
Chapter 1: INTRODUCTION
Chapter 2: EXECUTIVE SUMMARY
Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key Findings
3.2.1. Top investment pockets
3.3. Top winning strategies
3.3.1. Top Winning Strategies, by year, 2015-2018*
3.3.2. Top Winning Strategies, by development, 2015-2018* (%)
3.3.3. Top Winning Strategies, by company, 2015-2018*
3.3.4. Market Dynamics
126.96.36.199. Surge in incidence of infectious diseases
188.8.131.52. Increase in R&D activities for the development of combination drugs
184.108.40.206. Rise in funding for the development of antibiotics
220.127.116.11. Side effects associated with cephalosporin
18.104.22.168. Antibiotic resistance to cephalosporin
22.214.171.124. Lucrative opportunities in the emerging economies
3.4. Market Share Analysis, 2017
3.5. Porter's Five Forces Analysis
3.6. Novel Molecules in Cephalosporin Market
3.7. Combination Therapies in Cephalosporin Market
Chapter 4: CEPHALOSPORIN MARKET, BY GENERATION
4.2. First-Generation Cephalosporin
4.3. Second-Generation Cephalosporin
4.4. Third-Generation Cephalosporin
4.5. Fourth-Generation Cephalosporin
4.6. Fifth-Generation Cephalosporin
Chapter 5: CEPHALOSPORIN MARKET, BY TYPE
5.2. Branded Cephalosporin drugs
5.3. Generic Cephalosporin Drugs
Chapter 6: CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION
6.2. Cephaloshorin Injections
6.3. Oral Cephalosporin Drugs
Chapter 7: CEPHALOSPORIN MARKET, BY APPLICATION
7.2. Respiratory Tract Infection
7.3. Skin Infection
7.4. Ear Infection
7.5. Urinary Tract Infection
7.6. Sexually Transmitted Infection
Chapter 8: CEPHALOSPORIN MARKET, BY REGION
8.2. North America
Chapter 9: COMPANY PROFILES
9.1. Allergan PLC
9.2. Bristol-Myers Squibb Company
9.3. F. Hoffmann-La Roche Ltd.
9.4. GlaxoSmithKline PLC
9.5. Lupin Limited (Lupin Pharmaceuticals Inc.)
9.6. Merck & Co. Inc.
9.7. Novartis International AG (Sandoz)
9.8. Pfizer Inc.
9.10. Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/jwd5r5